Details for New Drug Application (NDA): 202425
✉ Email this page to a colleague
The generic ingredient in SITAGLIPTIN PHOSPHATE is sitagliptin phosphate. There are thirty-five drug master file entries for this compound. Six suppliers are listed for this compound. Additional details are available on the sitagliptin phosphate profile page.
Summary for 202425
| Tradename: | SITAGLIPTIN PHOSPHATE |
| Applicant: | Apotex |
| Ingredient: | sitagliptin phosphate |
| Patents: | 0 |
Pharmacology for NDA: 202425
| Mechanism of Action | Dipeptidyl Peptidase 4 Inhibitors |
Medical Subject Heading (MeSH) Categories for 202425
Suppliers and Packaging for NDA: 202425
| Tradename | Generic Name | Dosage | NDA | Application Type | Supplier | National Drug Code | Package Code | Package |
|---|---|---|---|---|---|---|---|---|
| SITAGLIPTIN PHOSPHATE | sitagliptin phosphate | TABLET;ORAL | 202425 | ANDA | Apotex Corp. | 60505-3643 | 60505-3643-3 | 30 TABLET, FILM COATED in 1 BOTTLE, PLASTIC (60505-3643-3) |
| SITAGLIPTIN PHOSPHATE | sitagliptin phosphate | TABLET;ORAL | 202425 | ANDA | Apotex Corp. | 60505-3643 | 60505-3643-9 | 90 TABLET, FILM COATED in 1 BOTTLE, PLASTIC (60505-3643-9) |
Profile for product number 001
| Active Rx/OTC/Discontinued: | RX | Dosage: | TABLET;ORAL | Strength | EQ 25MG BASE | ||||
| Approval Date: | Jan 20, 2026 | TE: | AB | RLD: | No | ||||
Profile for product number 002
| Active Rx/OTC/Discontinued: | RX | Dosage: | TABLET;ORAL | Strength | EQ 50MG BASE | ||||
| Approval Date: | Jan 20, 2026 | TE: | AB | RLD: | No | ||||
Profile for product number 003
| Active Rx/OTC/Discontinued: | RX | Dosage: | TABLET;ORAL | Strength | EQ 100MG BASE | ||||
| Approval Date: | Jan 20, 2026 | TE: | AB | RLD: | No | ||||
Complete Access Available with Subscription
